Single Recombinant and Purified Major Allergens and Peptides: How They Are Made and How They Change Allergy Diagnosis and Treatment

Overview

Journal Ann Allergy Asthma Immunol

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2017 Sep 12

PMID 28890016

Citations 20

Authors

Mirela Curin

Viktoriya Garib

Rudolf Valenta

Affiliations

Soon will be listed here.

Abstract

Objective: To review the current knowledge regarding recombinant and purified allergens and allergen-derived peptides.

Data Sources: PubMed, homepages relevant to the topic, and the National Institutes of Health clinical trial database were searched.

Study Selections: The literature was screened for studies describing purified and recombinant allergens and allergen-derived peptides. Studies relevant to the topic were included in this review.

Results: Advantages and drawbacks of pure and defined recombinant allergens and peptides over allergen extracts in the context of allergy research, diagnosis, and allergen immunotherapy are discussed. We describe how these molecules are manufactured, which products are currently available on the market, and what the regulative issues are. We furthermore provide an overview of clinical studies with vaccines based on recombinant allergens and synthetic peptides. The possibility of prophylactic vaccination based on recombinant fusion proteins consisting of viral carrier proteins and allergen-derived peptides without allergenic activity are also discussed.

Conclusion: During the last 25 years more than several hundred allergen sequences were determined, which led to a production of recombinant allergens that mimic biochemically and immunologically their natural counterparts. Especially in Europe, recombinant allergens are increasingly replacing allergen extracts in diagnosis of allergy. Despite many challenges, such as high cost of clinical trials and regulative issues, allergy vaccines based on recombinant allergens and peptides are being developed and will likely soon be available on the market.

Citing Articles

Pru p 3-specific IgE affinity is crucial in severe peach-allergy patients.

Li J, Yi X, Guan K, Yin J World Allergy Organ J. 2024; 17(6):100922.

PMID: 38966604 PMC: 11223113. DOI: 10.1016/j.waojou.2024.100922.

Non-Specific Lipid Transfer Protein Amb a 6 Is a Source-Specific Important Allergenic Molecule in Ragweed Pollen.

Grijincu M, Tanasie G, Zbircea L, Buzan M, Tamas T, Cotarca M Int J Mol Sci. 2024; 25(12).

PMID: 38928218 PMC: 11204090. DOI: 10.3390/ijms25126513.

Insect Cell-Expressed Major Ragweed Allergen Amb a 1.01 Exhibits Similar Allergenic Properties to Its Natural Counterpart from Common Ragweed Pollen.

Buzan M, Grijincu M, Zbircea L, Haidar L, Tamas T, Cotarca M Int J Mol Sci. 2024; 25(10).

PMID: 38791214 PMC: 11121294. DOI: 10.3390/ijms25105175.

Structural analysis of human IgE monoclonal antibody epitopes on dust mite allergen Der p 2.

Ball A, Khatri K, Glesner J, Vailes L, Wunschmann S, Gabel S J Allergy Clin Immunol. 2024; 154(2):447-457.

PMID: 38697404 PMC: 11409219. DOI: 10.1016/j.jaci.2024.04.017.

A genome-wide association study for allergen component sensitizations identifies allergen component-specific and allergen protein group-specific associations.

Morii W, Kasai K, Nakamura T, Hayashi D, Hara M, Naito T J Allergy Clin Immunol Glob. 2023; 2(2):100086.

PMID: 37780799 PMC: 10509904. DOI: 10.1016/j.jacig.2023.100086.

References

Haselden B, Kay A, Larche M . Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999; 189(12):1885-94. PMC: 2192970. DOI: 10.1084/jem.189.12.1885. View

Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H . The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999; 29(7):896-904. DOI: 10.1046/j.1365-2222.1999.00653.x. View

van Hage-Hamsten M, Kronqvist M, Zetterstrom O, Johansson E, Niederberger V, Vrtala S . Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the.... J Allergy Clin Immunol. 1999; 104(5):969-77. DOI: 10.1016/s0091-6749(99)70077-1. View

Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu D . The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999; 93(3):222-31. DOI: 10.1006/clim.1999.4795. View

Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt W, Twardosz A . Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 2002; 16(3):414-6. DOI: 10.1096/fj.01-0711fje. View

Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R . Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol. 2002; 127(4):259-68. DOI: 10.1159/000057742. View

Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M, Valent P . Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14677-82. PMC: 521981. DOI: 10.1073/pnas.0404735101. View

Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O . Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol. 1992; 97(4):287-94. DOI: 10.1159/000236135. View

Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O . Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005; 116(3):608-13. DOI: 10.1016/j.jaci.2005.06.004. View

10.

Altmann F . The role of protein glycosylation in allergy. Int Arch Allergy Immunol. 2006; 142(2):99-115. DOI: 10.1159/000096114. View

11.

Ebner C, Birkner T, Valenta R, Rumpold H, Breitenbach M, Scheiner O . Common epitopes of birch pollen and apples--studies by western and northern blot. J Allergy Clin Immunol. 1991; 88(4):588-94. DOI: 10.1016/0091-6749(91)90152-e. View

12.

Adams S, Barnett D, Walsh B, PEARCE R, Hill D, Howden M . Human IgE-binding synthetic peptides of bovine beta-lactoglobulin and alpha-lactalbumin. In vitro cross-reactivity of the allergens. Immunol Cell Biol. 1991; 69 ( Pt 3):191-7. DOI: 10.1038/icb.1991.28. View

13.

Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R . Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol. 1991; 88(6):889-94. DOI: 10.1016/0091-6749(91)90245-j. View

14.

Jacobsen L, Niggemann B, Dreborg S, Ferdousi H, Halken S, Host A . Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007; 62(8):943-8. DOI: 10.1111/j.1398-9995.2007.01451.x. View

15.

Van Ree R, Chapman M, Ferreira F, Vieths S, Bryan D, Cromwell O . The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy. 2008; 63(3):310-26. DOI: 10.1111/j.1398-9995.2007.01612.x. View

16.

Valenta R, Duchene M, Pettenburger K, Sillaber C, Valent P, Bettelheim P . Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science. 1991; 253(5019):557-60. DOI: 10.1126/science.1857985. View

17.

Pauli G, Larsen T, Rak S, Horak F, Pastorello E, Valenta R . Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008; 122(5):951-60. DOI: 10.1016/j.jaci.2008.09.017. View

18.

Mittermann I, Zidarn M, Silar M, Markovic-Housley Z, Aberer W, Korosec P . Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J Allergy Clin Immunol. 2010; 125(6):1300-1307.e3. DOI: 10.1016/j.jaci.2010.03.017. View

19.

Curin M, Reininger R, Swoboda I, Focke M, Valenta R, Spitzauer S . Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol. 2010; 154(3):258-63. DOI: 10.1159/000321113. View

20.

Worm M, Lee H, Kleine-Tebbe J, Hafner R, Laidler P, Healey D . Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011; 127(1):89-97, 97.e1-14. DOI: 10.1016/j.jaci.2010.11.029. View